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E-mail address: kchwher@uniklinikum-saarland.deAn association between hyperlipidemia and hyperhomocysteinemia (HHCY) has been suggested.
This link is clinically important in management of vascular risk factors especially in elderly people
and patients with metabolic syndrome. Higher plasma homocysteine (Hcy) was associated with
lower high-density lipoprotein (HDL)-cholesterol level. Moreover, HHCY was associated with dis-
turbed plasma lipids or fatty liver. It seems that hypomethylation associated with HHCY is respon-
sible for lipid accumulation in tissues. Decreased methyl group will decrease the synthesis of
phosphatidylcholine, a major phospholipid required for very low-density lipoprotein (VLDL) assem-
bly and homeostasis. The effect of Hcy on HDL-cholesterol is probably related to inhibiting enzymes
or molecules participating in HDL-particle assembly.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hyperhomocysteinemia (HHCY) and hypercholesterolemia are
linked to the development of atherothrombotic diseases. Few stud-
ies have shown that the risk associated with combined HHCY and
hypercholesterolemia is greater than that associated with only one
of these risk factors [1]. Therefore, an emerging aspect to reduce
cardiovascular diseases is maintaining concentrations of plasma
total homocysteine (Hcy) as well as that of cholesterol at low lev-
els. The mechanisms linking Hcy and lipid metabolism are not
thoroughly known.
Recent invaluable studies strongly demonstrate the importance
of the metabolic balance between SAM, SAH, choline, phosphati-
dylcholine (PC), phosphatidylethanolamine (PE) in Hcy metabo-
lism, hyperlipoproteinemia, liver function, and cardiovascular
disease. This review discusses the most important studies linking
these physiological pathways in health and disease conditions.chemical Societies. Published by E
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(W. Herrmann).2. Homocysteine metabolism
Homocysteine (Hcy) is a non-essential amino acid that is pro-
duced from demethylation of methionine. Hcy can be remethylat-
ed into methionine by means of vitamin B12-dependent
methionine synthase and 5-methyltetrahydrofolate as a methyl
donor. Hcy can be also catabolized into cysteine (the transsulfura-
tion pathway) via cystathionine beta synthase and cystathioninase,
both enzymes being vitamin B6-dependent. A third way to remove
Hcy is conversion to S-adenosylhomocysteine (SAH). The last reac-
tion is mediated by SAH-hydrolase and favors the SAH formation in
case of increased Hcy concentrations. S-Adenosyl methionine
(SAM) is a universal methyl donor that is formed from methionine
and converted into SAH after donating its methyl group. SAH is a
potent inhibitor of most known methyltransferases [2].3. Lipid metabolism
Plasma lipoproteins are unique particles with a hydrophobic
core containing triglycerides and esteriﬁed cholesterol and apoli-
poproteins on the surface. Lipoproteins show some similarity to
plasma membrane consisting of a surface layer phospholipids
and a core of non-polar lipids. Apo-AI and apoB are the principle
apolipoproteins associated with high-density lipoprotein (HDL)
and low-density lipoprotein (LDL), respectively. Very low-density
lipoprotein (VLDL) is the lipoprotein class of the lowest density
and the richest in triglycerides. This particle is formed in the liverlsevier B.V. All rights reserved.
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excreted from the liver in this nascent form, then it is transformed
into LDL after gradually losing its content of triglycerides. LDL is ta-
ken up by the liver and peripheral tissues via LDL-receptor. In con-
trast, HDL the lipoprotein responsible for the reverse transport of
cholesterol from peripheral tissues to the liver is the one with
the highest density and the richest in protein and phospholipids.
Additionally, HDL functions in transferring proteins into other lipo-
proteins, picks up cholesterol from other lipoproteins, and from
cell membranes, and esteriﬁes cholesterol by lecithin-cholesterol
acyltransferase (LCAT).
Elevated plasma concentration of LDL-cholesterol is a major
risk factor for cardiovascular disease. HDL protects from vascular
disease by mediating reverse cholesterol transport and by the
means of its direct antiinﬂammatory properties [3]. Low HDL-
cholesterol in combination with raised triglyceride levels is con-
sidered an atherogenic lipid proﬁle frequently associated with
the metabolic syndrome. The metabolic syndrome is a mutual soil
for HHCY as well as low HDL resulting in a high risk for coronary
diseases. Moreover, clinical studies on patients with coronary dis-
eases documented a negative association between Hcy and HDL-
cholesterol [4]. Therefore, interactions between Hcy and HDL-
metabolism could be clinically important. For example the cardio-
vascular beneﬁts of treatment with fenoﬁbrate [5] might be coun-
terbalanced by a sustained increase in the plasma concentration
of Hcy.PE
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Cholesterol and phospholipids play essential roles in all cellular
membranes. The plasma membrane is very rich in cholesterol, the
endoplasmic reticulum has an intermediate level, and the mito-
chondria have the lowest content of cholesterol. The intermem-
brane asymmetry appears to result, at least partially, from a
speciﬁc afﬁnity of certain phospholipids for cholesterol in the
order sphingomyelin > phosphatidylcholine > phosphatidylethanol-
amine [6].
In addition to its role in composition of cell membrane and
membrane dynamic function, PC is an important player in signal
transduction as a source of lipid second messengers [7] thus play-
ing a key roles in several metabolic pathways in the cells.
The role of methyl group metabolism in PC synthesis is summa-
rized in Fig. 1. PC is the methylated product of PE (3 methyl groups
are required) (Fig. 1). Phospholipid methylation in mammals is a
major SAM-consuming-pathway, since hepatic PC de novo synthe-
sis is responsible for about 50% of plasma Hcy levels [8]. Therefore,
synthesis of PC represents a cross point of SAM and phospholipid
metabolism.
In the liver, PC can be synthesized via two pathways, both of
which are linked to methyl group metabolism. The ﬁrst pathway
for PC synthesis is via the phosphatidyl ethanolamine methyltrans-
ferase (PEMT) pathway. The synthesis of approximately 30% of PC
in the liver is enhanced by PEMT that involves three sequentialCholine
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tion of 70% of PC in the liver, which can be made through the
cytidinediphosphocholine (CDP-choline) or Kennedy pathway
(Fig. 1). This biological reaction requires choline that is derived
either from the diet or from the catabolism of PC. The CDP-choline
and Hcy metabolism are linked via choline, because choline is a
precursor for betaine. The last compound is a methyl donor for
Hcy methylation via betaine homocysteine methyltransferase
(BHMT) in the liver. Therefore, disturbed Hcy metabolism results
in decreased SAM or increased SAH thus affecting the synthesis
of phospholipids (PC from PE).
The liver is the major site for lipid and Hcy metabolisms. The
expression of CBS and BHMT that mediate transsulfuration and
remethylation of Hcy, respectively, are especially high in the liver
[9]. Fat and cholesterol consumed with the diet are transported
to the liver as chylomicrons. In the liver, fat and cholesterol are
packaged into VLDL for transport through the blood to tissues that
require them. As PC is a component of VLDL particles, inadequate
PC can cause accumulation of fat and cholesterol in the liver. In-
creased hepatic cholesterol biosynthesis, retention of triglycerides
in the liver, and decreased plasma HDL and its protein content,
apo-AI, have been linked to HHCY in experimental studies despite
that plasma total cholesterol levels were either not or only slightly
changed [10–14].
A role for PC synthesis via the PE-methylation pathway in the
secretion, lipidation, or hydrolysis of VLDL has been suggested
[15,16]. 3-Deazadenosine is an SAH-hydrolase inhibitor and an
inhibitor of cellular methylation that caused reduction of PE-meth-
ylation (thus lower PC; higher PE/PC ratio), decreased VLDL secre-
tion and increased levels of intracellular triglycerides but did not
affect the total amount of apolipoproteins (apo-B48, apo-B100) se-
creted into the medium indicating that the effect was limited to
the lipidation of VLDL [16]. Another study documented that mice
fed a diet deﬁcient in methionine and choline had lower serum
cholesterol (77.2 mg/dl) and triglycerides (46.4 mg/dl) compared
to mice fed chew (104.5 and 120.5 mg/dl, respectively) or those
fed a methionine and choline supplemented diet (145.5 and
122.9 mg/dl, respectively) [17]. Mice fed a diet completely devoid
of methionine and choline had higher liver triglycerides and lower
liver cholesterol and phospholipids compared to mice fed a diet en-
riched with choline and methionine [17]. The authors observed a
profound suppression of steoroyl coenzyme A desaturase-1, an en-
zyme that enhances the metabolic rate [17].
Taken together, these results suggest that when triglyceride
transport out of the liver is inactive, the liver might try to produce
fewer amounts of the lipids and simultaneously enhance lipid oxi-
dation. Moreover, one can speculate that deﬁciency of methyl do-
nors (example choline and methionine deﬁcient diet) might be
associated with severe changes in lipid homeostasis in the liver
and probably the vascular system. It seems that hypomethylation
associated with HHCY is responsible for lipid accumulation in tis-
sues. Because Hcy metabolism is not restricted to the liver, one
might assume that other tissues such as the endothelial system
that are prone to accumulate lipids might be sensitive to HHCY.
In contrast, in the endothelial system where the role of BHMT in
Hcy metabolism is probably negligible [18], HHCY might enhance
the accumulation of lipids.5. HHCY disturbs lipid homeostasis; clinical observations
In addition to early cardiovascular events, patients with homo-
cysteinuria develop hepatic steatosis or ‘‘fatty liver” which is char-
acterized by enlarged, multinucleated hepatocytes containing
microvesicular lipid droplets [19]. An association between Hcy
and lipids has been also documented in studies on individuals withmild HHCY. In the Hordaland study that included 5917 subjects, a
higher intake of saturated fatty acids was positively associated
with higher concentrations of plasma Hcy. Concentrations of Hcy
were higher (by 8.8%) in the group with the highest intakes of sat-
urated fatty acids compared to that with the lowest intake [20].
These ﬁndings are not surprising, recalling the fact that liver is
the major organ where Hcy and lipid metabolism take place. The
molecular mechanism of fatty liver in HHCY is poorly understood.
Possible mechanism might be that the intake of saturated fatty
acids can lead to increased Hcy by increasing the production of PC
from PE via the PEMT pathway [20]. PEMT consumes three SAM
molecules for transforming PE to PC. The reaction produces three
SAH molecules that are hydrolyzed to Hcy via SAH-hydrolase
(Fig. 1). Another possible explanation could be that a diet rich in
fatty acids might contain more methionine, the precursor of Hcy.
Interesting observations were recently made in few patients
with SAH-hydrolase deﬁciency. This defect was associated with
only slightly elevated plasma Hcy (14–16 lmol/L), but a severe ele-
vation in SAH, and less elevation of SAM in blood [21]. Consider-
ably elevated liver enzymes (LDH and AST) have been observed
and liver biopsy showed extensive cytoplasmic lipid droplets in
electron microscopy [21]. In another patient with SAH-hydrolase
deﬁciency, plasma triglycerides were normal and the liver showed
marked structural abnormalities [22]. No speciﬁc reference to ste-
atosis has been reported in this case. The role of phospholipids in
membrane structure and function might explain the abnormalities
in the endoplasmic reticulum of liver biopsy [22]. This disorder
was also associated with markedly low plasma concentrations of
PC and free choline suggesting that increased SAH inhibited PEMT
and thus the production of PC from PE [21,22].6. Fatty liver and HHCY are mutual ﬁndings in chronic
alcoholism
Among the many macro- and micronutrients that are negatively
affected by chronic alcohol ingestion, are choline, betaine, methio-
nine and B-vitamins which are essential for the generation, trans-
port and transfer of one-carbon units to target molecules such as
phospholipids, SAM, DNA, and neurotransmitters [23]. Chronic
ingestion of methanol causes disturbances in methionine metabo-
lism in the liver, leading to increased Hcy, higher SAH, and lower
SAM [24]. The activity of methionine synthase and methionine
adenosine transferase is inhibited by alcohol. In contrast, the activ-
ity of BHMT is maintained and this leads to a higher consumption
and thus requirements of betaine required for Hcy methylation.
Furthermore, low concentrations of folate, vitamin B6 and betaine
are common in alcoholism and have been shown to enhance the
side effects of alcohol in the liver [25]. Additionally, alcohol con-
sumption causes fatty liver and hepatic steatosis. Hypomethylation
(i.e., low SAM/SAH ratio) and reduced PEMT activity in chronic
alcoholism may account for lipid accumulation in the liver [26–
29] (Fig. 2). In addition, supplementation of betaine or SAM can
protect the liver in chronic alcoholism (discussed below) suggest-
ing a role of BHMT and SAM in protecting against the toxic effects
of alcohol [26,27].7. HHCY and dyslipedemia; experimental studies
Both Hcy and lipids are toxic in vascular cells and hepatocytes
which could indicate interactions between the two pathways.
The interaction between lipids and Hcy metabolism has been
tested in several animal models with HHCY and/or hypercholester-
olemia (Table 1). The classical animal model for HHCY is homozy-
gous cystathionine beta synthase deﬁcient mice (CBS/). These
animals developed hepatic steatosis and atherosclerotic lesions
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Table 1
Studies on the effect of HHCY on blood or tissue lipids.
Conditions Hcy Plasma Hcy Blood lipids Liver/tissue lipids Reference
Mice fed methionine rich diet Hcy increased approximately 3-
fold
HDL; LDL; VLDL no signiﬁcant changes Liver not tested [35]
A methionine rich diet in mice
when added to an atherogenic
diet
Increased the size of the
atherosclerotic lesions containing
macrophage foam cells
Patients with homocysteinuria Severe HHCY (>100 lM) Fatty liver [20]
CBS/ mice Hepatic steatosis [13,31]
MTHFR/ Increased plasma Hcy Aortic lipid deposition [32]
ApoE/ mice fed a diet rich in
methionine and deﬁcient in
folate, B12 and B6
Increased Hcy Increased atherogenic lesion
compared to apoE/ mice
[33]
Rabbits fed a cholesterol rich diet
12 weeks
Developed atherosclerosis [34]
Methionine added to the
cholesterol rich diet
Enhance the lesion in animals
receiving a cholesterol rich diet
Betaine supplement 0.5% (W/V) " Hepatic SAM (2-fold) ; Hepatic triglycerides [109]
Control rats " Hepatic SAM (5-fold) ; Hepatic triglycerides
Ethanol-fed rats
Choline, 2 g Hcy 7.8–7.5, SAM/SAH 3.0–5.2* RBC membrane ratio of PC/PE was
lowered after 14 days
[108]
Lecithin, 2 g Hcy 8.6–8.5, SAM/SAH 3.9–4.9
Betaine, 3 g Hcy 7.3–6.2*, SAM/SAH 3.4–5.3*
For 14 day to children with cystic
ﬁbrosis
Methionine rich diet Plasma Hcy increased The methionine did not affect plasma
lipoprotein proﬁle
Methionine increased aortic
atherosclerotic lesion found in the
atherogenic diet group
[35]
Atherogenic diet + methionine
40 week
CBS//apoE/ mice vs CBS+/
+/apoE/
Plasma Hcy increased Increased total cholesterol, free
cholesterol, phospholipids, decreased
HDL-cholesterol
Decreased liver apo-AI protein
Decreased apo-AI protein in plasma
increase LCAT speciﬁc activity, decrease
LCAT substrate reactivity
[3]
CBS//apoE/mice vs CBS+/
+/apoE/
Plasma Hcy 210 vs 3.8 lM CBS//apoE/ mice had lower HDL-
cholesterol and lower triglycerides, and
higher total cholesterol
Double knock-out mice had more
cholesterol ester and triglycerides
deposition in the vessel well
[14]
MTHFR+/ mice compared to
MTHFR +/+ mice
62% lower apo-AI protein in MTHFR+/
mice
52% lower apo-AI protein in MTHFR+/
mice
[12]
Betaine supplement MTHFR+/
mice compared to MTHFR+/+
mice 1 year treatment
Reduced Hcy Increased apo-AI [43]
PC 2.6 g/day or placebo, for
2 weeks to healthy men
Reduced plasma Hcy by 18%, and
post-methionine-loading Hcy by
29% relative to placebo
Serum triglycerides increased after PC
treatment. serum LDL, HDL, and total
cholesterol did not change
[106]
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on CBS deﬁcient patients [19].
In methylenetetrahydrofolate reductase (MTHFR) deﬁcient
mice, decreased methylation capacity and aortic lipid deposition
have been observed [31]. Additionally, apoE deﬁcient (apoE/)
mice fed amethionine rich, folate, B12 and B6 deﬁcient diet showed
increased concentration of blood Hcy that was associated with in-
creased atherogenic lesions compared to apoE/ mice on a con-
trol diet [32]. Moreover, methionine rich diet for 12 weeks did not
independently cause atherosclerotic lesions but it did enhance the
lesions in animals receiving a cholesterol rich diet [33]. A further
study conﬁrmed that a methionine rich diet increased the size of
the atherosclerotic lesions containing macrophage foam cells in
mice when added to an atherogenic diet [34]. One study indicated
also that a diet rich in fat did not only elevate total cholesterol
but also doubled Hcy levels in animals [14]. These results suggest
that high intake of dietary cholesterol and fat might contribute to
the increase of Hcy levels, thus further increasing the risk of athero-
sclerosis. Taken together, HHCY can accelerate atherosclerosis un-
der dietary conditions that elevate plasma lipids and vice versa.
The enzyme SAH-hydrolase plays a major role in Hcy metabo-
lism and cellular lipid homeostasis. Its deﬁciency results in dereg-
ulated lipid metabolism, leading to an imbalance of phospholipids
and triglycerides synthesis, with probable implications for mam-
malian lipid-associated disorders [35]. Furthermore, data on cellu-
lar level demonstrated that depletion of SAH-hydrolase in yeast
results in massive accumulation of lipid droplets and triglycerides
during logarithmic growth [36]. SAH-hydrolase mediates SAH-
accumulation after treatment with Hcy and this metabolic condi-
tion causes inhibition of PE-methylation to PC, and subsequently
triglycerides accumulation [35]. Additionally, inhibition of SAH-
hydrolase decreases PC de novo synthesis and is accompanied by
an increase in triglyceride levels. Therefore, experimental studies
suggest that the conversion of PC to PE and the ratio of PE/PC are
key issues in the relationship between HHCY and dyslipedemia.
Phospholipid methylation via PEMT regulates methylation sta-
tus and vice versa. In line with this, reduced liver methylation
was accompanied by alterations in liver phospholipid metabolism
in CBS+/ mice [37]. HHCY mice had lower enzymatic activity of
PEMT in the liver compared with mice with normal Hcy. Higher
levels of PE in liver of HHCY mice led to higher PE/PC ratio, with
non-signiﬁcant differences in PC concentrations between HHCY
and control mice. Lower availability of methyl groups and lower
activity of PEMT in mice with HHCY might account for increased
PE, the demethylated precursor of PC [37].
Using a different approach, a PEMT knock-out mouse model, li-
ver phospholipid metabolism was compromised and the secretion
of VLDL from the liver was inhibited. Pemt/ mice fed a choline-
deﬁcient diet develop severe lipid pathologies after 3–4 d [38], had
a signiﬁcant decrease in hepatic and plasma PC levels, and had an
increase in hepatic triglyceride levels. In contrast, Pemt/ mice
fed a choline-supplemented diet did not display liver damage
and had normal hepatic and plasma PC levels as well as normal he-
patic triglycerides level [38]. The addition of a methyl donor, cho-
line, to the diet of Pemt/ mice was able to rescue the liver
damage [38]. Dietary choline can be converted into PC in the liver
via the CDP-choline pathway, thus ameliorating the effect of Pemt
deletion on phospholipid metabolism.
In a model of phospholipids disorders, Pemt/ mice show a
70% reduction in apo-B100 secretion from hepatocytes, a 50%
reduction in triglycerides secretion, and no change in PC [39].
The authors supposed that the PEMT pathway is essential for
secretion of apo-B100-containing-VLDL [39]. Thus lowered apo-
B100 in Pemt/ mice will cause reduction in triglycerides secre-
tion independent of PC amount. In contrast, in choline/methionine-
deﬁcient hepatocytes, insufﬁcient PC made by PEMT and CDP-cho-line pathways caused decreased secretion of both apo-B100 and
apo-B48 [40]. Hepatocytes obtained from choline-deﬁcient rats
showed impaired secretion of VLDL mediated by low PC synthesis.
This disturbance was corrected by the addition of either choline or
methionine to the medium as sources for methyl groups [40]. In a
further study on choline-deﬁcient animals, analysis of liver
phospholipid levels showed that PC/PE ratios had been signiﬁ-
cantly disrupted in the ER and the Golgi of liver cells in these ani-
mals, resulting in abnormal VLDL particles [41]. Choline deﬁciency
in this case results in inhibition of the CDP-choline pathway that is
responsible for PC production in the liver. Therefore, available
experimental studies agree that a shortage in methyl donors (cho-
line and methionine) is causally related to lipid accumulation in li-
ver cells. The involvement of PC is probable, but some studies did
not support this role.
In a study on CBS/ mice, the levels of choline containing
phospholipids were lowered by 68% in mice liver compared to
the levels in wild-type mice [13]. In the same study, CBS/ mice
had reduced liver apo-B100 and higher serum VLDL, suggesting
that HHCY impairs VLDL hydrolysis rather than enhancing liver
synthesis of VLDL [13]. Data obtained in another model of HHCY
(CBS+/, HHCY diet) [11] does not agree with the CBS/ mice
model mentioned above [13]. Increased hepatic VLDL triglyceride
secretion rates have been reported in CBS+/ mice fed Hcy-induc-
ing diet [11]. Future studies might test the suggestion that Hcy-in-
duced ER stress causes dysregulation of the endogenous sterol
response pathway, leading to increased hepatic biosynthesis and
uptake of cholesterol and triglycerides. Such a mechanism might
explain the development and progression of hepatic steatosis and
possibly atherosclerosis [11]. In addition, because phospholipids
have a major role in membrane ﬂuidity and molecule internaliza-
tion, studies should investigate whether increased PE/PC ratio
might cause disturbance in VLDL homeostasis in the liver.
Taken together, impaired methylation of PE to PC can affect
VLDL composition and secretion from the liver [40]. Methyl donors,
such as choline, methionine, or SAM might interchangeably ame-
liorate these disorders.8. Hcy and HDL-cholesterol
Most mechanistic studies relating HHCY to disturbed HDL-cho-
lesterol metabolism or assembly are derived from animal experi-
ments. CBS/ mice have lower HDL-cholesterol, higher serum
apo-B100, lower hepatic apo-B100, lower hepatic LCAT activity,
and higher free cholesterol [13]. Moreover, a reduction in HDL-cho-
lesterol has been reported in a double knock-out mice [CBS//
apoE/] compared to [CBS+/+/apoE/] mice (HDL; 19.9 vs
24.4 mg/dl) (Hcy; 210 vs 3.8 lM) [14]. Similarly, a different model
of HHCY, MTHFR+/ mice, developed atherosclerosis and had low
liver and plasma apo-AI, the protein content of the HDL particles
[12,42]. The mechanism by which Hcy can reduce HDL-cholesterol
is not entirely clear.
Several studies have tested the effect of Hcy on protein (mainly
apo-AI) and lipid contents of HDL particles. Lowered HDL-choles-
terol can be related to accelerated catabolism or lower production
of HDL molecule. A recent study found that elevated concentra-
tions of Hcy in vivo and in vitro enhanced the expression and the
protein level of adiponectin in the epididymal fat pad [43]. Betaine
supplemented mice showed increased adiponectin, however no
data about HDL-cholesterol was available [43]. Therefore, en-
hanced adiponectin production might be one explanation for accel-
erated catabolism of HDL-cholesterol in metabolic syndrome [44],
but this has to be further tested.
The hypothesis that HHCY might reduce the production of HDL
has been tested in mice fed a methionine rich diet for 7 weeks [45].
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key players in HDL production (apo-AI, LCAT, ABCA1) [45]. In line
with this, HHCY in mice was associated with a decreased activity
of hepatic thiolase and serum LCAT [13], two main enzymes in-
volved in HDL-metabolism. Another line of evidence suggested
that Hcy reduces the liver expression of apo-AI and thereby re-
duces levels of plasma apo-AI and HDL-cholesterol. Accordingly,
Liao et al. found that liver apo-AI protein, but not apo-AI mRNA,
was low in CBS//apoE/ mice [4] suggesting an effect on post
translational level. In addition, the authors found that Hcy reduced
the rate of plasma cholesterol esteriﬁcation catalyzed by the en-
zyme LCAT and increased clearance of HDL-cholesteryl esters from
plasma [4]. These results were conﬁrmed by Mikael et al., who also
found that Hcy reduces the synthesis of apo-AI [12]. Nevertheless,
apo-AI reduction in this study was a result of a decrease in apo-AI
mRNA [12]. Hcy may decrease apo-AI expression by lowering the
transcription factor, peroxisome proliferator receptor alpha (PPAR),
that participates in apo-AI transcription [12]. This mechanism
seems plausible since ﬁbrates (PPARa agonists) have been found
to regulate the expression of apo-AI thus increasing HDL-choles-
terol [46]. Accordingly, ciproﬁbrate has been shown to protect
from endothelial dysfunction in HHCY mice [47] probably by
mechanisms related to enhancing apo-AI production and HDL par-
ticles assembly. Another interesting ﬁnding is that PPARa infected
HepG2 cells expressed more MTHFR than non-infected cells. More-
over, increasing concentrations of Hcy (0–10 mM) caused de-
creased expression of PPARa in HepG2 cells [12]. These results
have also suggested that higher MTHFR activity in humans would
be associated with a higher apo-AI level mediated via lower Hcy
and thereby higher PPARa level.
In addition to reducing apo-AI expression, low PPARa is also
responsible for increased expression of cholesterol 7a-hydroxylase
(CYP7A1), a liver speciﬁc enzyme that mediates the 7a-hydroxyl-
ation of cholesterol, the rate limiting step in cholesterol conversion
into bile acids [48]. Bile acids enhance cholesterol absorption in the
intestine. The expression of PPARamight be lowered in HHCY sub-
jects [49] thus probably causing increased CYP7A1 and enhanced
intestinal cholesterol absorption. Recent studies observed that
the mRNA and the protein levels of CYP7A1 are increased in
MTHFR+/ mice compared to wild-type mice [12]. Collectively,
available results suggest that in HHCY, a decreased PPARa and an
increased CYP7A1 expression can cause enhanced cholesterol
absorption in the intestine as a result of increased production of
bile acids in the liver.
Paraoxonase-1 (PON1) is a serum HDL-associated phosphotries-
terase secreted mainly by the liver and shows a Hcy thiolactonase
activity [50] thus protecting from atherosclerosis [51]. Known
substrates for PON1 are oxidized phospholipids in HDL and LDL
[52], homocysteine thiolactone [53], and platelet-activating factor
[54]. Human studies showed that PON1 plays a role in the
physiological prevention of cardiovascular disease [55]. Therefore,
increased risk for atherosclerosis and dysfunctional HDL particles
in HHCY subjects might be related to low activity of PON1
[56].
Extrapolation of animal studies to humans deserves further
investigations. For example, there has been no association between
MTHFR C677T polymorphism and apo-AI level in a population with
a normal folate status [12]. A decreased MTHFR activity in TT sub-
jects can be compensated by sufﬁcient folate. Additionally, exper-
imental studies utilized supra-physiological concentrations of Hcy,
but the implication of the mild to moderate elevation of Hcy re-
mains unclear. Obviously, more studies should be conducted to
conﬁrm these ﬁndings in humans. Future studies should also test
whether DNA methylation is involved in altering gene expression
of enzymes participating in HDL-metabolism or assembly under
HHCY conditions.Taken together, HHCY is associated with lowered HDL-choles-
terol. This association is particularly important in patients with
diabetes or those with metabolic syndrome. The effect of Hcy on
HDL-cholesterol is probably related to inhibiting several enzymes
or steps participating in the assembly of HDL particles.
9. Other molecular mechanisms linking HHCY and dyslipedemia
The sterol regulatory element-binding protein (SREBP-1) is an
ER-membrane bound transcription factor that activates genes
encoding key enzymes in the cholesterol/triglyceride biosynthesis
and uptake pathways [57]. Hcy has been found to enhance the
expression of SREBPs and in this way it can enhance intracellular
accumulation of cholesterol [11]. Hcy causes protein misfolding in
the ER and activates the unfolded protein response (UPR) thus
causing increased expression of ER stress-response genes
[11,58]. An association between UPR activation and lipid biosyn-
thesis has been demonstrated in yeast [59] and human ﬁbroblasts
[60].
Hcy can activate UPR and increase the expression of the SREBP-
1 in human endothelial cells [11,58], in cultured human hepato-
cytes as well as in aortic smooth muscle cells [11]. Another study
demonstrated that diet-induced HHCY causes SREBP-1 activation
in the livers of apoE/ mice [11] and alcohol-fed mice [61]. The
effect of Hcy on SREBP activation is related to an increased cleav-
age under HHCY [11,62] and might be corrected by betaine, a
Hcy-lowering agent [61]. The observation that diet-induced HHCY
did not affect plasma lipid levels [34] might not exclude that the
endothelial system might be differently affected by HHCY leading
to tissue lipid accumulation.
Global DNA-hypomethylation has been suggested as a mecha-
nism linking Hcy to atherosclerosis in vascular smooth muscle
cells [63]. Increased concentration of SAH has been related to
the atherosclerotic lesions in apoE/ mice independent on Hcy
levels [64]. Concentration of SAH showed a positive correlation
to the area of the aortic disease in apoE/ mice fed a methio-
nine rich diet. Moreover, SAH levels were negatively related to
global DNA methylation in the aorta of these animals [64]. The
methylation of genes encoding functional proteins necessary for
lipid metabolism has been tested, and was found to be related
to the methylation potential (SAH/SAM ratio). For example, Fads2
is the gene encoding Delta6-desaturase, the enzyme that is in-
volved in the elongation and desaturation of linolenic acid and
linolic acid. Fads2 gene has been found to be sensitive to methyl-
ation status [37].
Oxidative stress is one mechanism by which Hcy might affect
lipoprotein particles and thereby damage endothelial cells [65].
Hcy can enhance hydroxyl radical generation and formation of oxi-
dized- [65], nitrated- [66], or homocysteinylated-LDL [67]. The
modiﬁed forms of LDL are more toxic than the native LDL and
are readily taken up by macrophages thus facilitating the initiation
and progression of the inﬂammatory response in the endothelial
lesions. Apo E/ mice treated with Hcy showed increased oxi-
dized-LDL [65]. This might enhance LDL uptake by scavenger
receptors in the aortic lesions or on monocyte or macrophages
and thus promoting atherosclerosis. Moreover, increased reactive
oxygen species under HHCY can stimulate components of the sig-
nal transduction thus causing endothelial dysfunction [68]. Some
evidence has suggested that the pro-oxidant effect of Hcy involves
endothelial nitric oxide synthase (eNOS) [69]. In one study, in vivo
supplementation of folate reduced plasma Hcy and protected LDL
and VLDL particles from oxidation [70]. The antioxidant effect of
folate can be related to Hcy-lowering or can indicate an indepen-
dent antioxidant effect of the vitamin, since a better effect for
5-methyltetrahydrofolate compared to folic acid has been found
[70].
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There is some evidence suggesting that the risk associated with
HHCY and hypercholesterolemia is higher than the risk associated
with one of these risk factors alone [1]. Therefore, it is conceivable
to think about using cholesterol-lowering treatment in combina-
tion with B-vitamins for the management of at risk patients. In
the FIELD study that included more than 9000 coronary patients
with type 2 diabetes, fenoﬁbrate caused only 11% reduction in cor-
onary events at the end of the study [5] but levels of Hcy increased
by approximately 35% (from 11.2 to 15.1 lmol/L). This might ex-
plain why the risk reduction was much less than expected in the
study.
In one study on men with mild hypercholesterolemia (mean
age 35 years), the effect of pravastatin (40 mg/day) on plasma
concentration of Hcy was tested in a randomized, double-blind,
placebo-controlled study [71]. The authors found a signiﬁcant
reduction of Hcy after 6-months [71]. Atorvastatin (10 mg/day)
induced no signiﬁcant changes in Hcy after 6 months in patients
with primary hypercholesterolemia [72]. In a recent review, Dier-
kes et al. concluded that HMG-CoA reductase inhibitors (statins)
seem not to inﬂuence Hcy, ﬁbric acid derivatives seem to increase
Hcy, and the effect of nicotinic acid and n3-fatty acids are not
conclusive [73]. Nevertheless, lipid-lowering drugs (ﬁbric acid
derivatives) might have an effect on Hcy independent on their li-
pid-lowering effect. To resolve this issue, it is important to test
whether lowering cholesterol by using a diet with standard en-
ergy and low cholesterol contents might reduce Hcy
concentrations.
A very interesting aspect of HMG-CoA reductase inhibitors is
that this treatment reduces cellular isoprenoids and induces syn-
thesis of phosphatidylcholine [74,75]. Statins may also impact
membrane phosphatidylserine that is synthesized from a choline/
serine exchange reaction. A recent study found that statins induce
drastic changes to the cellular pools of phosphatidylserine, sphin-
gomyelin and ceramid and limits the exposure of phosphatidylser-
ine at the cell surface by restricting the cellular pool of mevalonate
and thereby the isoprenoids [76]. Further studies should test
whether statins modify SAM levels via increasing PC synthesis that
is a major SAM-consuming-pathway.
Therefore, available clinical studies using different lipid-lower-
ing drugs could not conﬁrm a unique effect on Hcy. However, it
seems prudent to test for HHCY in patients receiving ﬁbric acid
derivatives and to then ensure sufﬁcient status of B-vitamins.11. Effect of Hcy-lowering treatment on blood lipids
11.1. Folate, vitamin B12, vitamin B6
The hypothesis that Hcy metabolism can affect blood lipids
gained further attention in the last few years. Therefore, one might
speculate that lowering Hcy by means of the B-vitamins can affect
blood lipids. However, there are no well-designed studies that
aimed at investigating the effect of vitamin B12, B6, and/or folic
acid on blood lipids.
In a 6-week trial, Olthof et al. tested the effect of folic acid
(0.8 mg/day) on blood lipids in healthy subjects with Hcy levels be-
low 26 lmol/L [77]. Folic acid supplementation lowered Hcy by
approximately 21%. Changes of concentrations of total cholesterol,
HDL-cholesterol, LDL-cholesterol and triglycerides were not signif-
icant at the end of the treatment [77]. Another study aimed at
investigating the effect of oral folic acid (5 mg/day) for 4 weeks
on endothelial function in patients with familial hypercholesterol-
emia [78]. Supplementation of folic acid improved endothelial
function without signiﬁcant changes in plasma lipids [78].Few studies were conducted in end-stage renal disease where
an elevated plasma concentration of Hcy and dyslipidemia are very
common and are recognized risk factors for arteriosclerosis in this
group of patients. In a 3-months placebo-controlled study on dial-
ysis patients, folic acid supplementation (5 mg/day) caused Hcy-
lowering by 33% [79]. Additionally, levels of total cholesterol,
LDL-cholesterol, and triglyceride decreased signiﬁcantly in patients
on peritoneal dialysis but not in those on haemodialysis [79]. In a
study on 12 haemodialysis patients, Hcy-lowering therapy using
folic acid (5 mg) and vitamin B6 (250 mg) for 26 months caused
lowering of LDL-cholesterol, increased HDL-cholesterol, and a
slight reduction in total cholesterol and triglycerides [80].
In most of the above mentioned studies, the duration of the
vitamin trials was short and probably not sufﬁcient to show an ef-
fect [77]. Trials with longer durations were more effective [80], but
this has to be conﬁrmed in larger scales. Moreover, most studies in-
cluded only a small number of patients which might be insufﬁcient
for detecting an effect. In addition, most studies excluded patients
with HHCY, which might also impact the expected inﬂuence of
lowering Hcy [77].
11.2. Betaine
Betaine is formed by choline oxidation via choline dehydroge-
nase in the kidney and the liver [81,82]. Betaine is a methyl donor
in the remethylation of Hcy into methionine via BHMT [83].
Accordingly, plasma concentrations of Hcy are negatively related
to that of betaine [84], and betaine supplementation can reduce
plasma Hcy [77]. In contrast, inhibition of hepatic BHMT in mice
by 60–90% by repeated injection of S-(d-carboxylbutyl)-DL-homo-
cysteine for 1–8 h caused increase in plasma Hcy by 2.7–8-fold
and a 65% reduction in SAM/SAH ratio compared to mice given a
saline injection [85].
The role of betaine supplementation in lipid metabolism has
been investigated in few clinical studies. Betaine seems to be inver-
sely correlated to several components of the metabolic syndrome
thus protecting against coronary vascular risk [86]. Plasma betaine
was positively associated with HDL-cholesterol and inversely asso-
ciated with serum triglycerides and non-HDL-cholesterol [86]. Fur-
thermore, in subjects attending a lipid clinic, betaine was inversely
related to apo-B and body fat [87]. These results are not consistent
however, with those from supplementation studies. Doses of 4–
6 g/d betaine raised plasma total cholesterol, and LDL-cholesterol,
and did not affect HDL-cholesterol in healthy people [77]. This ef-
fect was already evident 2-weeks after starting the supplementa-
tion. Therefore, a dual effect for betaine seems to add more
complexity to the role of this compound in lipid metabolism.
Animal studies shed more light on the dual effect of betaine.
Betaine supplementation improved the atherogenic lipid proﬁle
in HHCYmice [42]. In MTHFR+/ andMTHFR+/+ mice, betaine sup-
plementation (450 mg/kg/ day) caused increased apo-AI expres-
sion in the liver of supplemented compared to non-
supplemented mice [42]. Additionally, mice receiving betaine had
lower plasma triglycerides and higher HDL-cholesterol compared
to the non-supplemented ones. Moreover, stimulation of BHMT
by a methionine restricted, betaine enriched diet caused increased
secretion of VLDL and a 45% reduction in liver triglycerides [88]. In-
creased apo-B mRNA, VLDL apo-B protein content, and triglycer-
ides production, in addition to decreased hepatic triglycerides
may suggest that stimulation of BHMT might mobilize hepatic tri-
glycerides by increasing apo-B available for VLDL turn-over [88].
These results support the role of BHMT in lipid metabolism in addi-
tion to Hcy metabolism. However, this effect seems to be strictly
related to the presence of other methyl donors like methionine
in the diet. Betaine supplement in combination with methionine
sufﬁcient diet seems to enhance the anti-atherogenic lipid proﬁle.
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causes a negative effect on lipid proﬁle probably related to ineffec-
tive SAM production by betaine alone.
Betaine has been often tested in studies on alcoholic liver dis-
ease. Animals fed with alcohol develop fatty liver inﬁltration. Beta-
ine administration (0.5% for 2–4 weeks) doubled the hepatic levels
of SAM in control animals and increased the levels of hepatic SAM
by 4-fold in the ethanol-fed rats [89–91]. The ethanol-induced
inﬁltration of triglycerides in the liver was also reduced by the
feeding of betaine to the ethanol-fed animals. Unlike SAM and
betaine, folate treatment was not able to restore the diseased liver
in alcoholism [92]. These ﬁndings support that betaine can en-
hance the activity of liver BHMT and provides more SAM for liver
methyltransferases such as PEMT. Betaine administration has the
capacity to elevate hepatic SAM and to prevent the ethanol-in-
duced fatty liver [90]; probably by normalizing PC synthesis and
thereby VLDL homeostasis.
The effect of betaine on blood lipids could be related to increase
in synthesis of SAM and, eventually, glutathione, decreasing the
hepatic concentrations of Hcy and SAH, and increasing the SAM/
SAH ratio. These metabolic conditions lead to the activation of
PEMT, increased PC synthesis, and formation of VLDL for the export
of triglycerides from the liver to the circulation [92].
Taken together, evidence on the role of betaine in lipid metab-
olism is currently not sufﬁcient to recommend supplementing this
compound. Observational studies suggested a favorable effect, but
treatment studies are not conclusive. One factor that should be
considered is the dose and the duration of betaine treatment, in
addition to other sources of methyl groups in the diet. Short term
variations of blood lipids after betaine treatment (2 weeks) might
be related to redistribution of lipids between blood and liver. An-
other factor that might have contributed to variations between
the studies is the analytical methods used for quantifying concen-
trations of betaine and choline.
11.3. Choline
Choline is an important nutrient and a source of methyl groups
in the diet. Choline is obtained either from diet or from the catab-
olism of PC. The most abundant choline derivative, phosphatidyl-
choline, is formed from PE in hepatocytes via PEMT (Fig. 1).
Choline is a precursor for acetylcholine, membrane phospholipids,
and lipoproteins thereby serving essential biological functions. He-
patic PC is required for VLDL secretion and constitutes an impor-
tant component of bile [93]. Choline can also be converted into
betaine by means of a mitochondrial enzyme, choline dehydroge-
nase thus it is considered the metabolic precursor of betaine
[94]. Because betaine is a methyl donor for Hcy remethylation
via BHMT, it is not surprising that choline, the precursor of betaine,
is negatively related to Hcy concentration [77,86].
Choline and folate statuses seem to interrelate. On the one
hand, a choline deﬁcient diet for 2 weeks caused 30–40% lower he-
patic folate in rats [95]. This was reversed after feeding the animals
with choline [95]. Additionally, a combined deﬁciency of choline
and methionine for 5 weeks caused 50% lower hepatic folate [96].
Animal studies have also shown that, choline deﬁciency caused
50% lower liver SAM [97,98], fatty liver [99], and reduced liver glu-
tathione [100], the most important antioxidant in animal cells. On
the other hand, folate deﬁciency [101] or antifolate treatment
(methotrexate) [95,97] caused lowered hepatic choline, especially
PC. These results suggest that a greater amount of folate might
be required for maintaining essential methylation reactions in
the liver when dietary choline is not sufﬁcient. Liver folate can
be used for generating SAM and thus enhancing PC synthesis in
choline deﬁcient cases. Alternatively, folate deﬁciency might in-
crease the requirement for choline as a methyl donor.Choline deﬁciency interferes also with lipid metabolism and
causes non-alcoholic fatty liver [40,102] thus reﬂecting the role
of choline in lipid homeostasis. In accordance with this, a diet deﬁ-
cient in choline caused triglycerides accumulation in the liver of
mice fed a low or a high-fat diet [103]. Choline deﬁciency in rats
promoted accumulation of triglycerides in the liver (6.5-fold) and
reduction of triglycerides concentration in plasma by 60% [104].
Plasma VLDL levels were reduced in choline-deﬁcient rats, but
the concentration of plasma HDL-cholesterol was not affected
[104]. A study in humans [105] showed that choline deprived diet
(<50 mg/day) for 42 days did not affect serum concentrations of
the lipids (total-, LDL-, HDL-cholesterol) or plasma SAM and SAH,
but caused fatty liver or muscular damage in the majority of men
and post-menopausal women included in the study [105]. The
study did not show the response of serum concentration of triglyc-
erides to choline supplementation. These results collectively indi-
cate that choline deﬁciency causes lower turn-over of hepatic
lipids, retention of lipids in the liver, reduced secretion of VLDL
from the liver and thereby, lower plasma triglycerides.
Choline administered as phosphatidylcholine is a Hcy-lowering
agent [106]. In a study on healthy men, supplementation of phos-
phatidylcholine equivalent to 2.6 g/day choline for 2 weeks low-
ered fasting plasma Hcy by 18% and post-methionine-load Hcy
by 29% compared to the placebo [77]. In addition, plasma concen-
trations of choline were positively associated with serum concen-
trations of triglycerides in a study that included over 7000
middle age and elderly men and women [86]. Moreover, plasma le-
vel of choline showed an inverse relation with HDL-cholesterol
[86]. This association has been conﬁrmed by showing the effect
of choline supplementation on blood lipids. In one study, phospha-
tidylcholine supplementation increased blood triglycerides con-
centration without changing concentrations of total-, LDL- and
HDL-cholesterol [77]. The observed fatty liver could suggest that
choline deﬁciency can cause reduced PC and thus reduced secre-
tion of VLDL from the liver. In several other studies, lecithin, a cho-
line containing phospholipid, has been used for its cholesterol-
lowering effect that is probably related to enhancing the activity
of LCAT, the enzyme that removes cholesterol from the tissues
[107]. The hypothesis is, choline supplementation can increase
PC, thus increasing VLDL turn-over and thereby plasma triglycer-
ides, while increasing HDL-cholesterol because of enhancing LCAT.
In a recent study, the effects of betaine (3 g/d), choline (2 g), and
lecithin (2 g) on Hcy cycle metabolites were tested in children with
cystic ﬁbrosis [108]. Supplementation with choline or betaine de-
creased SAH, increased SAM, and glutathione. Supplementation
with choline or lecithin increased plasma methionine and SAM
[108]. An association between betaine and choline and component
of the metabolic syndrome was reported, with only betaine being
associated with a better risk proﬁle [86]. However, supplementa-
tion studies of both micronutrients are not conclusive. We antici-
pate that the ratio of choline/betaine could be a meaningful
marker in whether one of these micronutrients can shift the risk
proﬁle in one direction. This index could be related to the activity
of choline dehydrogenase. A higher choline dehydrogenase activity
will produce more betaine (lower choline/betaine ratio), increase
SAM, reduces Hcy and probably also blood lipids. A low choline
dehydrogenase activity will cause a higher choline/betaine ratio,
less SAM and probably will drive the choline into PC and produc-
tion of VLDL.
Obviously, more studies should be conducted on this issue test-
ing for all sources of methyl group donors (folate, methionine,
betaine, and choline). Future studies should investigate the effect
of one methyl donor on Hcy and plasma phospholipids, keeping
the other donors stable. There is currently no recommendation
for using choline as cardiovascular protector, before results from
such studies are available.
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partly via methyl group metabolism. Strong evidence suggested
that deﬁciency of methyl group donors and HHCY disturb
phospholipid metabolism thus affecting the assembly or secretion
of VLDL from the liver. Another line of evidence suggested a direct
role for Hcy in inducing ER stress or regulating enzymes responsi-
ble for HDL-cholesterol metabolism. A very interesting aspect to be
tested in future studies is enhancing lipid metabolism via reducing
Hcy and increasing the endogenous production of SAM.References
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